Summary of Recent Deal Activity
- PDF / 95,871 Bytes
- 8 Pages / 612 x 792 pts (letter) Page_size
- 95 Downloads / 191 Views
Int J Pharm Med 2006; 20 (3): 201-208 1364-9027/06/0003-0201/$39.95/0 © 2006 Adis Data Information BV. All rights reserved.
Summary of Recent Deal Activity Drug Discovery Technologies Companies
Type of deal
Details
Abbott Laboratories, Celera Genomics
R&D agreement
Abbott Laboratories, Tripos Ablynx, Kirin Brewery
R&D agreement
Affymetrix, Iconix Pharmaceuticals
R&D agreement
Alnylam Pharmaceuticals, Gen-Probe
Licensing agreement
Alnylam Pharmaceuticals, Integrated DNA Technologies
Licensing agreement
AstraZeneca, BioSystems International
R&D agreement
AvidBiotics
Licensing agreement
AvidBiotics
Licensing agreement
Abbott Laboratories has selected two Celera Genomics’ antigen targets for further investigation and potential therapeutic development. Under the terms of the collaboration agreement, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott. The collaboration encompasses the development of therapeutic antibodies and small-molecule drugs against overexpressed cell-surface proteins that have been associated with cancer and identified as therapeutic targets through proteomics research at Celera Genomics. Tripos has entered into a chemistry collaboration with Abbott Laboratories to design, synthesise and purify high-quality, novel, drug-like compounds to expand Abbott’s compound file collection. Tripos and Abbott will collaborate in library design, analysis and synthesis. Ablynx has signed a research collaboration and license agreement with Kirin Brewery to collaborate on a defined project that exploits the unique structural and functional properties of Nanobodies™ for use as novel therapeutic products. Nanobodies are a novel class of therapeutic proteins that combine the beneficial features of conventional antibodies with desirable properties of small-molecule drugs. Nanobodies have the affinity and selectivity of conventional antibodies, yet are only a fraction of their size. Affymetrix and Iconix Pharmaceuticals have signed a collaborative agreement to develop solutions to aid the study of the toxicological and pharmacological properties of drugs and drug candidates. The collaboration will aim to significantly accelerate the drug-development process by combining Affymetrix’s GeneChip® microarray technology with Iconix’s DrugMatrix® 640 compound reference database and analysis software. Together, Affymetrix’s GeneChip expression arrays and Iconix’s analysis methods will provide detailed information on a drug candidate’s toxicological liabilities and pharmacological properties. Using such tools, researchers will be able to quickly compare gene-expression profiles to the Iconix’s Drug Signatures® library to help predict the impact that gene-expression changes may have on biological pathways critical to the body’s toxic response to drugs. Such information could help researchers to better prioritise candidates and make preclinical development decisions faster. Gen-Probe has granted Alnylam Pharmaceuticals nonexclusive rights to use Gen-Probe’s hyb
Data Loading...
